ARVN

Over the past six months, Arvinas's stock price has declined by approximately 27.92%. Key events include strong Q2 2026 earnings and the FDA approval of VEPPANU (vepdegestrant) in August 2026, which led to a stock surge of over 12%. This was followed by a Wells Fargo downgrade from Overweight to Equal-Weight, causing a sharp fall in shares. In August 2026, VEPPANU was out-licensed to Rigel Pharmaceuticals, including a $62.5 million payment to Arvinas. The Q1 2026 report in May showed a smaller-than-expected loss but a steep year-over-year revenue decline due to the wind-down of Pfizer milestone payments. In April 2026, the company entered an agreement with Novartis to develop and commercialize ARV-766.